Mutational analysis of candidate tumor-associated genes in acute megakaryoblastic leukemia

Leukemia

Volumn 23, Issue 11, 2009, Pages 2159-2160

  Bhat, R ^a,b   Malinge, S ^b   Gamis, A S ^c   Sorrell, A D ^d   Hilden, J M ^e   Ketterling, R P ^f   Paietta, E ^g   Tallman, M S ^b   Crispino, J D ^b  

^a CHILDREN'S MEMORIAL HOSPITAL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c CHILDREN S MERCY HOSPITAL   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^e Peyton Manning Children's Hospital   (United States)

^f MAYO CLINIC   (United States)

^g MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; JANUS KINASE 2; JANUS KINASE 3; MYOCYTE ENHANCER FACTOR 2; NOTCH1 RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE SHP 2; STEM CELL FACTOR; TRANSCRIPTION FACTOR FLI 1; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR GATA 2;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE MEGAKARYOCYTIC LEUKEMIA; ARTICLE; CANCER SURVIVAL; DOWN SYNDROME; EVENT FREE SURVIVAL; HUMAN; IMMUNOPHENOTYPING; INCIDENCE; KARYOTYPE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SOMATIC MUTATION; SURVIVAL TIME; TRISOMY 21;

DNA MUTATIONAL ANALYSIS; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MEGAKARYOBLASTIC, ACUTE; SIGNAL TRANSDUCTION; THROMBOPOIESIS; TRANSCRIPTION FACTORS;

EID: 70450265342     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2009.159     Document Type: Article

References (8)

1. Tallman MS, Neuberg D, Bennett JM, Francois CJ, Paietta E, Wiernik PH et al. Acute megakaryocytic leukemia: The Eastern Cooperative Oncology Group experience. Blood 2000; 96: 2405-2411.
2. Barnard DR, Alonzo TA, Gerbing RB, Lange B, Woods WG. Comparison of childhood myelodysplastic syndrome, AML FAB M6 or M7, CCG 2891: Report from the Children's Oncology Group. Pediatr Blood Cancer 2007; 49: 17-22.
3. Gamis AS. Acute myeloid leukemia and Down syndrome evolution of modern therapy - state of the art review. Pediatr Blood Cancer 2005; 44: 13-20.
4. Wickrema A, Crispino JD. Erythroid and megakaryocytic transformation. Oncogene 2007; 26: 6803-6815.
5. Malinge S, Ragu C, Della-Valle V, Pisani D, Constantinescu SN, Perez C et al. Activating mutations in human acute megakaryoblastic leukemia. Blood 2008; 112: 4220-4226.
6. Hussein K, Bock O, Theophile K, Schulz-Bischof K, Porwit A, Schlue J et al. MPLW515L mutation in acute megakaryoblastic leukaemia. Leukemia 2009; 23: 852-855.
7. Grabher C, von Boehmer H, Look AT. Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nat Rev Cancer 2006; 6: 347-359.
8. Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007; 7: 673-683.